NCT06327100: Open Label Phase 2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) |
|
|
| Not yet recruiting | 2 | 33 | US | Ruxolitinib, Jakafi, INCB018424, INC424, Tasquinimod | M.D. Anderson Cancer Center, Active Biotech AB | Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-Essential Thrombocytosis Myelofibrosis | 05/29 | 05/31 | | |